Aromatase Inhibitors and Breast Cancer
- 26 February 2009
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1155 (1) , 162-173
Abstract
We have developed a breast cancer intratumoral aromatase model to simulate the postmenopausal breast cancer patient in order to compare the antitumor efficacy of aromatase inhibitors (AIs) and antiestrogens (AEs). The AI letrozole sustained growth inhibition longer than the AE tamoxifen. Nevertheless, eventually tumors began to grow despite continued treatment. Estrogen receptor‐α (ER‐α) levels decreased below control levels concomitant with increased phosphorylation of ER‐α and unaltered progesterone receptor (PgR) levels. Expression of Her‐2, p‐Shc, Grb‐2, p‐Raf, p‐Mekl/2, and p‐MAPK was increased in the letrozole‐resistant tumors. When cells isolated from letrozole‐resistant tumors (LTLTCa cells) were treated with inhibitors of the Her‐2 signaling pathway, such as trastuzumab (herceptin), ER‐α was restored. Furthermore, sensitivity of LTLTCa cells to AIs and AEs was regained. These findings suggest cross‐talk between ER and Her‐2 signaling. To prevent activation of the Her‐2 pathway and resistance to AIs, mice were treated with a combination of an AI anastrozole and the ER downregulator fulvestrant. This resulted in no increase in Her‐2 and p‐MAPK levels, and tumor growth was significantly inhibited. Thus, blocking both ER and Her‐2 signaling delayed development of resistance to AIs. This hypothesis was supported by the finding that growth of letrozole‐resistant tumors was reduced when xenografts were treated with trastuzumab combined with letrozole. In addition, resistance to letrozole could be reversed by discontinuing letrozole. Our findings indicate that after letrozole treatment is stopped, the antitumor effect of letrozole can be restored when the AI treatment is resumed.Keywords
This publication has 28 references indexed in Scilit:
- Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to EstrogenCancer Research, 2009
- Stopping Treatment Can Reverse Acquired Resistance to LetrozoleCancer Research, 2008
- Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft ModelCancer Research, 2008
- Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor LetrozoleCancer Research, 2005
- Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitationsThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antiseraOncogene, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Adrenal glands of mouse and rat do not synthesize androgensLife Sciences, 1992
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984